Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.47 Analyst target: $8.33 Upside: 466.67%
OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
See the full interactive analysis & chart →Informational only — not investment advice.